Papp K, Menter A, Leonardi C, et al. - Given that brodalumab is efficacious for the treatment of moderate‐to‐severe plaque psoriasis through 52 weeks, researchers tested the safety and effectiveness of brodalumab through 120 weeks, including following withdrawal and retreatment. Study participants were randomized to brodalumab (n = 222) or placebo (n = 220) at baseline. According to results, effectiveness in those receiving brodalumab after placebo was sustained through week 120. No new safety signals have been found. Such results indicate that after discontinuation and retreatment, brodalumab is efficient and safe for continuous long-term treatment of psoriasis and supports the potential for response.